518990-32-4Relevant articles and documents
Discovery of N-(Indazol-3-yl)piperidine-4-carboxylic Acids as ROR?3t Allosteric Inhibitors for Autoimmune Diseases
Anthony, Neville,Azevedo, Rita,Barr, Kenneth,Cals, Jos,Correll, Craig C.,Daniels, Matthew,Deshmukh, Sujal,Ferguson, Heidi,Hegde, Laxminarayan G.,Karstens, Willem Jan,Lapointe, Blair T.,MacLean, John,Moy, Lily Y.,Nagpal, Sunil,Oubrie, Arthur,Palte, Rachel L.,Parthasarathy, Gopal,Richard Miller, J.,Sciammetta, Nunzio,Simov, Vladimir,Van Der Stelt, Mario,Van Eenenaam, Hans,Wesley Trotter, B.,Woodhouse, Janice D.,Zhang, Hongjun
supporting information, (2020/02/06)
The clinical success of anti-IL-17 monoclonal antibodies (i.e., Cosentyx and Taltz) has validated Th17 pathway modulation for the treatment of autoimmune diseases. The nuclear hormone receptor RORγt is a master regulator of Th17 cells and affects the prod
ALKYNYL ALCOHOLS AND METHODS OF USE
-
Page/Page column 184, (2015/03/13)
The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over- activation of NF-kB signaling is observed.
3-CYCLOHEXENYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF
-
Page/Page column 43-44, (2014/03/22)
Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
